No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques, prostate-specific antigen (PSA) levels at time of salvage radiotherapy (SRT), use of SRT ± salvage androgen deprivation therapy based on PSA levels, and the interval to biochemical failure.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Yokomizo, A. et al. Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401). Eur. Urol. https://doi.org/10.1016/j.eururo.2019.11.023 (2019).
Zaorsky, N. G. et al. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol. 10, 457–474 (2014).
Calais, J. et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286–1294 (2019).
Panebianco, V. et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur. Radiol. 23, 1745–1752 (2013).
Tendulkar, R. D. et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J. Clin. Oncol. 34, 3648–3654 (2016).
Stish, B. J. et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J. Clin. Oncol. 34, 3864–3871 (2016).
Carrie, C. et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 20, 1740–1749 (2019).
Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417–428 (2017).
Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727–737 (2016).
Pollack, A. et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiation therapy: the NRG Oncology/RTOG 0534 SPPORT Trial. Int. J. Radiat. Oncol. Biol. Phys. 102, 1605 (2018).
The authors declare no competing interests.
EAU guidelines: https://uroweb.org/guideline/prostate-cancer/
NCCN guidelines: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
About this article
Cite this article
Zaorsky, N.G., Kishan, A.U. Salvage therapy at biochemical recurrence of prostate cancer. Nat Rev Urol (2020). https://doi.org/10.1038/s41585-020-0290-3